CA-CLOUDBLUE
23.3.2020 14:02:09 CET | Business Wire | Press release
CloudBlue, an Ingram Micro business, announced today the newest update to CloudBlue Connect, a unique catalog and channel automation platform.
With the accelerated proliferation of products, channels, marketplaces and customers, CloudBlue helps businesses perform for today’s business goals and simultaneously transform for tomorrow’s opportunities by enabling speed to market and revenue for all products, across all channels.
“The latest version of CloudBlue Connect gives customers even greater operational efficiency and scalability to more easily grow their businesses,” said Tarik Faouzi, vice president of CloudBlue. “Our core mission is to help customers accelerate their time to market and revenue through increased business automation and continuous innovation.”
The CloudBlue Connect release (version 19) features an out-of-the-box plugin on the Zapier platform, a web-based process automation platform. This offers providers and their vendors greater extensibility to communicate and automate processes with thousands of applications with no development effort—unlocking unlimited opportunities to new types of integrations.
Another key feature is the new, highly requested Subscription module, which enables providers and their vendors to view their respective recurring subscriptions from a consolidated pane. Additionally, CloudBlue Connect can now trigger automated billing requests for recurring subscriptions at renewal times, which is a benefit for organizations with legacy commerce systems incapable of initiating these recurring billing requests.
Besides the Zapier plugin and Subscription module, these are other new features:
- Expanded compatibility with usage-based products: The ability to add products that require complex usage reporting.
- Shopping cart validation and reservation: Automatically validate the availability of a product quantity and reservations before checkout.
- Unified product definition: Vendors can more specifically define products from one interface, and providers can find all product-related information in one place.
- Extended SKU definition : Vendors can create a detailed SKU hierarchy so that providers can better understand their portfolio for clearer bundling and upselling and cross-selling paths.
“We developed these enhancements as part of our long-term strategy for CloudBlue Connect and as a response to our customer feedback,” Faouzi said. “With businesses today being impacted by the current climate and the need for greater operational flexibility, our cloud and digital capabilities enable companies to look beyond the traditional ways of working to work from anywhere in the most efficient manner possible.”
Organizations lose 20% to 30% of revenue every year due to inefficient processes, according to market research firm IDC. CloudBlue solves the challenges businesses face in the era of proliferation with efficient solutions that get customers to market faster without significant investments and the sacrifice of revenue.
More information about CloudBlue Connect is available here .
About CloudBlue
CloudBlue provides a hyperscale platform with hypergrowth products and services that allows providers to launch and manage an omni-product, multi-tier and multi-channel marketplace. With CloudBlue, providers can access and capitalize on a hyperconnected ecosystem of 200+ top-selling vendors, 200+ leading brands and more than 80,000 partners globally. Many of the world’s best-known software and SaaS vendors, digital service providers, technology distributors, tech manufacturers, managed services providers, and value-added resellers rely on CloudBlue’s leading CloudBlue Commerce and CloudBlue Connect platforms to automate, aggregate and sell both their own cloud services as well as those from third-party vendors. CloudBlue powers more than 200 of the world’s largest provider cloud marketplaces, which collectively represent more than 30 million enterprise cloud subscriptions.
More at www.cloudblue.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200323005012/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom